MEDICAMEN BIOTECH
|
MEDICAMEN BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.22 | 5.16 | 7.47 | 11.64 | 12.19 |
| CEPS(Rs) | 12.55 | 10.71 | 13.05 | 16.67 | 16.92 |
| DPS(Rs) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Book NAV/Share(Rs) | 190.02 | 161.29 | 157.52 | 145.25 | 113.56 |
| Tax Rate(%) | 18.26 | 33.65 | 27.39 | 13.59 | 17.67 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.49 | 8.87 | 13.11 | 17.28 | 20.86 |
| EBIT Margin(%) | 8.41 | 8.37 | 10.46 | 14.51 | 17.36 |
| Pre Tax Margin(%) | 6.06 | 6.08 | 7.29 | 12.10 | 15.67 |
| PAT Margin (%) | 4.95 | 4.03 | 5.29 | 10.46 | 12.90 |
| Cash Profit Margin (%) | 8.60 | 8.38 | 9.25 | 14.98 | 17.90 |
| Performance Ratios | |||||
| ROA(%) | 2.95 | 2.24 | 3.34 | 5.87 | 7.11 |
| ROE(%) | 4.23 | 3.23 | 4.94 | 9.13 | 11.25 |
| ROCE(%) | 6.00 | 5.78 | 8.46 | 10.85 | 12.94 |
| Asset Turnover(x) | 0.60 | 0.55 | 0.63 | 0.56 | 0.55 |
| Sales/Fixed Asset(x) | 1.40 | 1.18 | 1.34 | 1.11 | 0.96 |
| Working Capital/Sales(x) | 1.46 | 1.88 | 2.39 | 1.74 | 2.29 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.71 | 0.85 | 0.74 | 0.90 | 1.04 |
| Receivable days | 139.09 | 139.40 | 122.66 | 166.45 | 183.01 |
| Inventory Days | 122.01 | 136.43 | 106.29 | 93.37 | 50.92 |
| Payable days | 196.13 | 226.08 | 215.82 | 311.49 | 316.67 |
| Valuation Parameters | |||||
| PER(x) | 31.10 | 93.43 | 51.31 | 56.31 | 52.79 |
| PCE(x) | 17.91 | 44.96 | 29.37 | 39.31 | 38.05 |
| Price/Book(x) | 1.18 | 2.99 | 2.43 | 4.51 | 5.67 |
| Yield(%) | 0.45 | 0.21 | 0.26 | 0.15 | 0.16 |
| EV/Net Sales(x) | 1.63 | 3.95 | 2.81 | 5.92 | 7.00 |
| EV/Core EBITDA(x) | 13.53 | 31.09 | 19.48 | 31.13 | 31.32 |
| EV/EBIT(x) | 19.40 | 47.24 | 26.85 | 40.82 | 40.35 |
| EV/CE(x) | 1.02 | 2.69 | 2.18 | 3.93 | 3.59 |
| M Cap / Sales | 1.54 | 3.77 | 2.72 | 5.89 | 6.81 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 21.67 | -9.35 | 27.29 | 22.02 | 2.42 |
| Core EBITDA Growth(%) | 15.41 | -20.02 | -3.59 | 3.86 | 26.35 |
| EBIT Growth(%) | 22.30 | -27.45 | -8.27 | 2.00 | 11.90 |
| PAT Growth(%) | 49.43 | -30.95 | -35.54 | -1.14 | 22.82 |
| EPS Growth(%) | 40.09 | -30.95 | -35.86 | -4.53 | 22.82 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.19 | 0.16 | 0.16 | 0.14 | 0.19 |
| Current Ratio(x) | 2.54 | 2.11 | 1.89 | 1.98 | 1.69 |
| Quick Ratio(x) | 1.75 | 1.31 | 1.31 | 1.50 | 1.36 |
| Interest Cover(x) | 3.58 | 3.66 | 3.31 | 6.03 | 10.32 |
| Total Debt/Mcap(x) | 0.16 | 0.06 | 0.06 | 0.03 | 0.03 |
Compare Financial Ratios of peers of MEDICAMEN BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MEDICAMEN BIOTECH | ₹345.1 Cr | -11.4% | -20.6% | -15.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,204.0 Cr | -1% | -5.5% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹238,497.0 Cr | -2.6% | -3.9% | 38.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹170,481.0 Cr | -1.7% | -10.2% | 30.5% | Stock Analytics | |
| CIPLA | ₹108,012.0 Cr | 0.9% | -3.2% | -15.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,207.0 Cr | -0.6% | 1% | -0.1% | Stock Analytics | |
MEDICAMEN BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MEDICAMEN BIOTECH | -11.4% |
-20.6% |
-15.2% |
| SENSEX | -1.6% |
-2.3% |
-11.5% |
You may also like the below Video Courses
